Replies to post #500 on Weikang Bio-Technology Group (fka WKBT)

[pappy]

Yes earnings,cash,A/R,B.V. all made dramatic improvements in spite the lower revenue due to the capsule recall & the general slowdown in China.

Starting in January 2013 outstanding warrants will start expiring.

Nice to see they are still a fully reporting pinkie.

p.s. A thought.... If the CEO has decided to spend money to contine being a fully audited company in compliance with the SEC.

He must be entertaining thoughts of ways to improve his share values in the future.

After all he is by far the "current" largest shareholder of wkbt.